We have located links that may give you full text access.
In situ bioremediation of 1,2-dibromoethane (EDB) in groundwater to part-per-trillion concentrations using cometabolism.
Journal of Contaminant Hydrology 2018 September 26
1,2-Dibromoethane (ethylene dibromide; EDB) is a probable human carcinogen that was historically added to leaded gasoline as a scavenger to prevent the build-up of lead oxide deposits in engines. Studies indicate that EDB is present at thousands of past fuel spill sites above its stringent EPA Maximum Contaminant Level (MCL) of 0.05 μg/L. There are currently no proven in situ options to enhance EDB degradation in groundwater to meet this requirement. Based on successful laboratory studies showing that ethane can be used as a primary substrate to stimulate the aerobic, cometabolic biodegradation of EDB to <0.015 μg/L (Hatzinger et al., 2015), a groundwater recirculation system was installed at the FS-12 EDB plume on Joint Base Cape Cod (JBCC), MA to facilitate in situ treatment. Groundwater was taken from an existing extraction well, amended with ethane, oxygen, and inorganic nutrients and then recharged into the aquifer upgradient of the extraction well creating an in situ reactive zone. The concentrations of EDB, ethane, oxygen, and anions in groundwater were measured with time in a series of nested monitoring wells installed between the extraction and injection well. EDB concentrations in the six monitoring wells that were hydraulically well-connected to the pumping system declined from ~ 0.3 μg/L (the average concentration in the recirculation cell after 3 months of operation without amendment addition) to <0.02 μg/L during the 4-month amendment period, meeting both the federal MCL and the more stringent Massachusetts MCL (0.02 μg/L). The data indicate that cometabolic treatment is a promising in situ technology for EDB, and that low regulatory levels can be achieved with this biological approach.
Full text links
Related Resources
Trending Papers
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Anti-Arrhythmic Effects of Heart Failure Guideline-Directed Medical Therapy and Their Role in the Prevention of Sudden Cardiac Death: From Beta-Blockers to Sodium-Glucose Cotransporter 2 Inhibitors and Beyond.Journal of Clinical Medicine 2024 Februrary 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app